{
    "nctId": "NCT06428682",
    "briefTitle": "Role of TXA in Patients Undergoing Breast Free Flap Reconstruction",
    "officialTitle": "Role of Intravenous Tranexamic Acid Use in Patients Undergoing Breast Free Flap Reconstruction: Randomized Controlled Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Blood Loss, Surgical",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Delta Hemoglobin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All female patients who are 18 years or older who will undergo unilateral or bilateral abdomen-based free flap breast reconstruction at UVA Medical Center\n\nExclusion Criteria:\n\n* Subjects with ages \\<18 years\n* Allergy to TXA\n* Subjects who has contraindications to TXA: anyone who has active intravascular thrombosis or anyone with subarachnoid hemorrhage\n* Subjects who have anemia (defined as baseline hemoglobin \\<8 g/dL\n* Subjects who cannot read or understand English\n* Subjects who are pregnant",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}